Search Results

You are looking at 101 - 110 of 452 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Joleen M. Hubbard and Axel Grothey

% of patients undergoing total colectomy will have 5 or more bowel movements per day, and 30% will have issues with fecal incontinence. 34 , 35 Adjuvant Therapy for Stage II and III Colon Cancer Patients with high-risk stage II and III disease

Full access

Clayton A. Smith and Lisa A. Kachnic

improve 10-year OS compared with observation (51.8% vs 48.4%; P =.32). 13 Although early analysis demonstrated a DFS benefit of adjuvant therapy for patients with ypT0–2 (hazard ratio [HR], 0.64; 95% CI, 0.45–0.91; P =.13), this benefit was not observed

Full access

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag, and Tanios Bekaii-Saab

the question as to the utility of the current standard of care, which is 6 months of perioperative systemic therapy. Given the unclear utility of adjuvant therapy after preoperative therapy has been administered, the clinical importance of pathologic

Full access

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

dissection for melanoma . J Clin Oncol 2004 ; 22 : 3677 – 3684 . 70 Cascinelli N Belli F MacKie RM . Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised

Full access

Crystal S. Denlinger

as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer . J Clin Oncol 2012 ; 30 : 3792 – 3799 . 5. Bonneterre J Roché H Kerbrat P . Long-term cardiac follow-up in relapse

Full access

Donna Trauth and Lori J. Goldstein

1998 ; 17 : 101 . 65 Eifel P Axelson JA Costa J . National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3 2000 . J Natl Cancer Inst 2001 ; 93 : 979 . www

Full access

Ali Raza Khaki, V.K. Gadi, and Vinay Prasad

LA , Davis GJ , . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980 – 991 . 11181660 10.1200/JCO.2001.19.4.980 2. Wishart GC , Azzato EM , Greenberg

Full access

David S. Ettinger

fusion gene EML-4 ALK . This mutation seems to be mutually exclusive with the EGFR and KRAS mutation in the phase I study. Adjuvant Therapy In 2004, the International Adjuvant Lung Cancer Trial showed an approximately 5% survival advantage

Full access

Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea

should be tempered by maximal preservation of neurologic function. What does seem to be apparent is that STR without any adjuvant therapy is associated with a poor prognosis. There have been 16 cases presented in the literature that have undergone STR or

Full access

Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter

predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate